Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 93

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 93
---
                                            |

| - | 30% capture represents approximately 110,000 patients annually |

| - | U.S. contribution alone: ~27,000 patients (~$17M in revenue) |

Revenue SOM

| - | 30% of $220M global market = ~$66–70M/year |

SOM reflects a tangible, realistic revenue line,
not the theoretical ceiling (TAM).

Even at 30% penetration, the opportunity is substantial
and defensible due to:

| - | Lack of effective alternative therapies for resistant gonorrhea |

| - | High clinical urgency and CDC/WHO surveillance prioritization |

| - | Concentrated patient pools in developed markets with strong 
 reimbursement systems                                       |

Final SOM Opportunity

~110,000 patients/year treatable

~$70M/year realistic revenue potential at 30%
global penetration of the addressable market for Ceftriaxone-Resistant Gonorrhea

These estimates are illustrative only and based on assumptions regarding TAM/SAM/SOM, pricing and epidemiology. . Our product candidate is still in preclinical development
and has not been approved by any regulatory authority. We do not yet know the final dosage, or number of injections required per treatment
course, and actual pricing will depend on multiple factors including clinical results, regulatory approval, reimbursement, adoption,
and competition.

Epidemiology and Estimated Market Opportunity for Methicillin-Resistant Staphylococcus Aureus (MRSA), Including Vancomycin-Resistant (VRE) Cases

MRSA is a leading cause of hospital- and community-acquired
infections. The CDC estimates over 1.2 million MRSA infections annually in the U.S. with another 423,000 hospitalized patients colonized
with the bacteria [8]. While Vancomycin is standard therapy, resistance and treatment failures are increasing, prompting interest in
second-line options including liposomal Amphotericin B [9].

Our novel formulation of systemic Liposomal-Mupirocin
is positioned to target serious systemic MRSA infections, especially in Vancomycin-resistant or refractory cases.

Pricing Benchmark and Market Assumptions

| - | Liposomal Amphotericin B (per dose):                                                
 ~$120 (average worldwide without US)- ~$341 in the US [4], per course ~$1700-~4,700 |

| - | Assumed Liposomal Mupirocin IV                                                               
 pricing: ~$220 per dose, with a total course